Objectives: To characterize a new zinc-finger nuclease (ZFN) that targets close to the sequence of the 32 bp deletion polymorphism in the CCR5 gene, and to generate cells resistant to HIV-1 strains that use CCR5. CCR5D32 is a naturally occurring deletion that provides genetic resistance to R5-tropic HIV-1. The specificity and efficacy of a newly identified target for CCR5 gene editing, near the CCR5D32 sequence (ZFNCCR5D32), was assessed as well as its ability to generate cells resistant to HIV infection with reduced off-target effects.
Introduction
In the initial phase of HIV infection, HIV strains with CCR5 tropism are most commonly found. 1 The most relevant polymorphism described to date for CCR5 is a 32 bp deletion (CCR5D32) that introduces a premature stop codon, generating a truncated protein.
Homozygosity for CCR5D32 provides genetic resistance to HIV-1 infection, while heterozygosity is associated with delayed progression, 2 without additional apparent immunological dysfunction. The relevance of the CCR5D32 allele was strengthened by the report of the 'Berlin patient', the first case of functional HIV-1 cure. 3 The Berlin patient is an HIV-positive subject who received a bone marrow transplant from a donor homozygous for the CCR5D32 allele, resulting in immune system reconstitution with CCR5D32 homozygous cells and resistance to R5 HIV strains. No clinical signs of infection had been shown in the patient .4 years after transplantation in the absence of antiretroviral therapy. 3, 4 The development of new tools for genome editing has created new and varied experimental options for the development of new strategies for HIV-1 treatment. 5 Gene therapy strategies using zinc-finger nucleases (ZFNs) have been successfully applied to modify the CCR5 gene in human and mouse cells, 6 strategies that may eventually lead to a putative functional cure for HIV-infected people.
Here, we describe the design of a ZFN targeting the CCR5 gene, which mimics the naturally occurring CCR5D32 polymorphism by disrupting the CCR5 gene within the deleted region (ZFNCCR5D32). Gene editing using ZFNCCR5D32 induced an artificial CCR5D32 phenotype in vitro and cells became resistant to R5 HIV-1 infection. In addition, the specificity of the targeted sequence near the D32 polymorphism of the CCR5 gene revealed no significant off-site cutting events, suggesting minimal potential negative effects for ZFNCCR5D32.
Methods

Vectors
CompoZr
TM Knockout ZFNs targeting the CCR5 gene (ZFNCCR5D32) were obtained from Sigma-Aldrich Biotechnology (St Louis, MO, USA). ZFNs were designed against the sequence ACCTGCAGCTCTCATTTTCCATACAGTCAGTA, corresponding to the deleted region in the CCR5D32 polymorphism (Figure 1a as described previously. 7 Each ZFN-CCR5 plasmid (0.5 mg) was delivered into 1.5×10 5 cells previously seeded in 24-well plates. Five days after transfection, CCR5 expression was assessed and negative cells were CCR5 ZFN without detectable off-target effects 1757 JAC sorted. The effect of ZFNCCR5D32 was assessed by the Cel-I assay. 6 Single-cell clones were obtained by limiting dilution.
Quantification of CCR5 gene expression (mRNA)
RNA was extracted using the Qiagen RNeasy Mini Extraction Kit (Qiagen) and reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Relative CCR5 gene expression was measured by two-step quantitative RT -PCR and normalized to GAPDH gene expression. 8, 9 Sequence analysis of targeted CCR5 gene in TZM-bl cells Genomic DNA from sorted cell clones was extracted using the QIAamp DNA Blood Mini Kit (Qiagen) and the CCR5 gene was PCR amplified. PCR products were cloned into the pGEM-T Easy Vector System (Promega, Spain) and plasmids were sequenced using ABI PRISM Big Dye Terminator Cycle Sequencing technology (Applied Biosystems). Sequences were analysed using Sequencher 4.5 software (Gene Codes Corporation, Ann Arbor, MI, USA).
Virus production and infections
HIV-1 viral strains BaL and NL4-3 were obtained from the MRC Centre for AIDS Reagents (London, UK). TZM-bl cells (1.5×10 4 ) were seeded in 96-well plates and infected with the BaL or NL4-3 viral strain. Cells were lysed 72 h after infection and b-galactosidase activity was quantified. 9 Supplementary methods are available as Supplementary data at JAC Online.
Results
Plasmids encoding ZFNCCR5D32 were transiently expressed into TZM-bl cells. Single-round treatment of TZM-bl cells with ZFNCCR5D32 induced a modest increase (from 0.6% to 2.4%) in CCR5-negative cells (Figure 1b ) compared with mock-transfected cells. To improve the efficiency of ZFN and speed up the selection of edited single-cell clones, a strategy involving the sorting of treated cells was applied, after which CCR5-negative cells were enriched up to 78% of total cells (Figure 1b) .
Monoclonal populations of ZFNCCR5D32-edited and sorted cells were selected by the limiting dilution procedure in 96-well plates. Once grown, plates were replicated and positive wells were further analysed for the presence of CCR5. Genetic modifications introduced by ZFNCCR5D32 in CCR5-negative cells were characterized by cloning the CCR5 coding region, obtaining at least 30 different CCR5 sequences from each plasmid clone. Both deletions and insertions were identified, ranging from a single bp deletion to a 25 bp deletion, and deletions were more frequent than insertions [ Figure 1c and Figure S1 (available as Supplementary data at JAC Online)].
Analysis of CCR5 truncation by flow cytometry allowed the identification of a number of clones that were effectively negative for CCR5 expression at the cell surface, whereas no changes in CD4 or CXCR4 coreceptor expression were observed (Figure 2a) . CCR5 truncation was confirmed by the surveyor mutation detection assay of the individual clones obtained (Figure 2b) . Analysis of CCR5 gene expression showed between 70% and 100% reduction in CCR5 mRNA, depending on the clone tested (Figure 2c) , compared with wild-type or mock-transfected controls. Taken together, these results demonstrate that ZFNCCR5D32 induces a potent abrogation of CCR5 coreceptor expression at the mRNA and protein levels (Figure 2a and c) .
Functional assessment of ZFNCCR5D32 was conducted by challenging the generated cell clones with the R5-tropic BaL HIV-1 strain or the X4-tropic NL4-3 strain (Figure 2d-g ). As expected, no differences in infection compared with control cells were seen when ZFNCCR5D32-treated clones were infected with the NL4-3 strain (Figure 2d and f) . Conversely, infection of ZFNCCR5D32 cells by the R5-tropic strain BaL was drastically inhibited (75% infection rate for mock-treated cells versus 0.2% for the most highly inhibited of the three clones evaluated; P .0.0001; Figure 2e and g), indicating that ZFNCCR5D32 genetic truncation was able to completely prevent HIV-1 infection.
By using in silico analysis, putative off targets for ZFNCCR5D32 were tested. A total of 28 different off targets in the human genome were identified as putative cut sites for ZFNCCR5D32. However, deep sequencing data at the 28 regions of interest in human K562 cells edited by ZFNCCR5D32 detected no off-target activity (Table S1 , available as Supplementary data at JAC Online), further demonstrating the high specificity and efficacy of ZFNCCR5D32.
Discussion
Antiretroviral therapy has enabled the transformation of HIV infection into a manageable chronic disease. 10 However, the unique report of a sterilizing cure for HIV-1 infection relied on a bone marrow transplant from a donor homozygous for the CCR5D32 polymorphism that conferred genetic resistance to HIV-1 R5 infection. 3, 4 The broader applicability of transplanting bone marrow CCR5D32 haematopoietic progenitors may be hampered by the risks associated with allogeneic transplantation and the difficulty of obtaining matched donors. Thus, gene editing tools might be a suitable alternative by which to generate autologous CCR5 knockout cells. 6, 11 ZFNs, transcription activator-like effector nucleases (TALENs) and CRISPR/Cas RNA-guided DNA endonucleases are transformative tools that have the potential to revolutionize biological research and affect personalized medicine. Indeed, gene editing technologies have expanded the ability to manipulate and study model organisms, and support the promise of correcting the genetic defects behind many diseases, although many important questions and challenges remain to be addressed, such as effectiveness as therapeutic agents, risk of off-site cleavage and methods for optimal in vivo delivery into cells. Here, we describe the generation and potent antiviral capacity of a novel ZFN targeting the site of the D32 deletion within the CCR5 gene that is intended to overcome these challenges. We validated the suitability and safety of a novel ZFN design, ZFNCCR5D32, which is able to generate CCR5-negative clones completely resistant to the HIV-1 BaL R5-tropic viral strain, without off-site effects, in a widely accepted in vitro model for HIV-1 infection.
Although gene therapy using ZFNs targeting HIV coreceptors has been previously reported (Table S2 , available as Supplementary data at JAC Online), and at least three clinical trials are currently ongoing (NCT00842634, NCT01044654 and NCT01252641), no other ZFN has been reported for the D32 sequence and only an alternative strategy, using a TALEN, has been described to date.
12 -14 TALEN technology differs from ZFN in the DNA binding domain, and consists of 15 -20 tandem repeats rather than the triplets of nucleotides for ZFN, thus achieving high DNA specificity and cleavage activity. 15 However, Badia et al.
their larger size limits their delivery by size-restricted vectors such as adeno-associated virus, which has been shown to accommodate ZFN genes such as ZFNCCR5D32 (Table S2) . Perhaps the main concern with using gene editing technologies is the potential risk of off-site cleavage, which may induce undesired negative effects. The use of high-throughput methods that enable comprehensive profiling of off-target cleavage sites has provided insights into the stringency of target recognition for each sequence design. 16, 17 By contrast with a previously described ZFN targeting CCR5, for which 10 -14 possible off-target sites were identified (including the highly homologous gene CCR2), 16, 17 the assessment of potential off-target sites for ZFNCCR5D32 revealed a much better profile, with high sequence divergence from CCR2 (14 of 27 bases) and no detectable cutting at other genomic regions, highlighting the importance of the chosen target sequence to reduce undesired cleavage sites (Table S2) .
Distinct from the site-specific nucleases described, the CRISPR/ Cas system has recently emerged as a potentially simple and efficient alternative to ZFNs and TALENs. Although these programmable RNA-guided DNA endonucleases have demonstrated multiplex gene disruption capabilities, more exhaustive studies are required in order to evaluate the utility of this system, in particular regarding the potential for off-target effects, as it remains unclear whether it can afford the recognition selectivity necessary to ensure single-site specificity in complex genomes.
